J&J Baby-Care Sales Down With Second Talc Cancer Trial Underway
This article was originally published in The Rose Sheet
Executive Summary
A second trial examining an alleged link between perineal use of J&J's talcum-based powder products and ovarian cancer began April 11, following a February jury verdict in the same court that ordered the firm to pay $72m in damages to the family of an ovarian cancer casualty. J&J's baby-care performance weighed on overall results in the firm's first fiscal quarter, while OTC product sales continue to rebound.